Compare SA & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SA | HAE |
|---|---|---|
| Founded | 1979 | 1971 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | N/A | 1991 |
| Metric | SA | HAE |
|---|---|---|
| Price | $34.01 | $57.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $65.00 | ★ $86.00 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 03-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.84 |
| EPS | N/A | ★ 3.65 |
| Revenue | N/A | ★ $1,318,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.86 |
| P/E Ratio | ★ N/A | $15.82 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.40 | $47.32 |
| 52 Week High | $37.99 | $87.32 |
| Indicator | SA | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 23.44 |
| Support Level | $31.68 | $55.95 |
| Resistance Level | $34.70 | $60.50 |
| Average True Range (ATR) | 2.15 | 2.35 |
| MACD | 0.04 | -0.58 |
| Stochastic Oscillator | 57.61 | 15.70 |
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.